VirTech Bio
Beverly, US · Founded 2013 · Delaware corporation
VirTech Bio develops OxyBridge, a human-derived hemoglobin-based oxygen carrier (HBOC) intended as a blood substitute for time-critical trauma patients in hemorrhagic shock and for pre-transplant donor organ perfusion. The product is aimed at military and civilian trauma care and organ transplantation, using an ultra-polymer design to deliver oxygen and maintain blood pressure without refrigeration.
BiotechHealthtechMedical Devices
Founders & leadership
JT
Joseph TuckerExecutive Officer
MV
Matias VidalCo-Founder & Executive Chairman
DH
Dallas HackCEO & Director, Medical Affairs
Reported raises · per SEC filings
Form D private placements▶$500KraisedJun 2016 · 5 investors · BiotechnologyRule 506(b)
▶$500KraisedJun 2016 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph TuckerExecutive Officer
- Matias VidalExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $50K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseSpecial Operations Command | Phase II | 2018 | $1.8M |
| Department of DefenseSpecial Operations Command | Phase I | 2018 | $148.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $239K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.